Multidrug resistance increment in a human colon carcinoma cell line by colchicine

作者: M. J. Ruiz Gómez , L. Gil , A. Souviron , M. Martínez Morillo

DOI: 10.1007/BF03179774

关键词: Multiple drug resistanceReversionVinblastineBiologyDrug resistancePharmacologyVincristineFlow cytometryColchicineVerapamil

摘要: The most important mechanism in drug resistance is the multidrug (MDR) phenomenon. It possible to select MDR cells by vitro exposure cytotoxic agents. due hyperexpression of P-glycoprotein (PGp) that take drugs out from cells. In this study, a colchicine resistant subline (HCA-2/1cch) was selected human colon adenocarcinoma after short period exposure, as an model selection. These showed cross-resistance other drugs, which were not present medium during relative 3.32 for colchicine, 3.15 vinblastine, 2.62 vincristine and 5.22 mitomycin C. levels assayed flow cytometry. found significant increase 2.35 1.59 had occurred peak mean channel fluorescence, respectively, indicating increment expression relation parental line. Moreover, verapamil (10 μg/ml) produced partial reversion resistance. sensitisation rates 7.41 1.25 2.36 1.17 data obtained suggest weeks) dose (0.5 sufficient produce This could be higher level P-Gp expression.

参考文章(20)
Philippe Gros, Marie Azzaria, Jeffrey F. Lemontt, Increased mdr gene expression and decreased drug accumulation in multidrug-resistant human melanoma cells. Cancer Research. ,vol. 48, pp. 6348- 6353 ,(1988)
James Croop, Frank Baas, Alfred Schinkel, Johannes Bras, Kimberly Stieglitz, Kimberly Stieglitz, Robert J. Arceci, Monoclonal antibody to an external epitope of the human mdr1 P-glycoprotein. Cancer Research. ,vol. 53, pp. 310- 317 ,(1993)
Mauro Boiocchi, Giuseppe Toffoli, Mechanism of multidrug resistance in human tumour cell lines and complete reversion of cellular resistance. European Journal of Cancer. ,vol. 28, pp. 1099- 1105 ,(1992) , 10.1016/0959-8049(92)90465-E
M.L. Neale, N. Matthews, Development of tumour cell resistance to tumour necrosis factor does not confer resistance to cytotoxic drugs. European Journal of Cancer and Clinical Oncology. ,vol. 25, pp. 133- 137 ,(1989) , 10.1016/0277-5379(89)90061-8
Brian Leyland-Jones, William Dalton, George A. Fisher, Branimir I. Sikic, Reversal of multidrug resistance to cancer chemotherapy. Cancer. ,vol. 72, pp. 3484- 3488 ,(1993) , 10.1002/1097-0142(19931201)72:11+<3484::AID-CNCR2820721615>3.0.CO;2-L
Michael P. LaQuaglia, Elizabeth B. Kopp, Barbara A. Spengler, Marian B. Meyers, June L. Biedler, Multidrug resistance in human neuroblastoma cells. Journal of Pediatric Surgery. ,vol. 26, pp. 1107- 1112 ,(1991) , 10.1016/0022-3468(91)90684-L
R�is�n NicAmhlaoibh, Mary Heenan, Irene Cleary, Samantha Touhey, Colette O'Loughlin, Carmel Daly, Gabriel Nu�ez, Kevin J. Scanlon, Martin Clynes, Altered expression of mRNAs for apoptosis-modulating proteins in a low level multidrug resistant variant of a human lung carcinoma cell line that also expresses mdr1 mRNA. International Journal of Cancer. ,vol. 82, pp. 368- 376 ,(1999) , 10.1002/(SICI)1097-0215(19990730)82:3<368::AID-IJC10>3.0.CO;2-E
Norbert Kartner, Deanna Evernden-Porelle, Grace Bradley, Victor Ling, Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies Nature. ,vol. 316, pp. 820- 823 ,(1985) , 10.1038/316820A0